Mutations in EGFR (L858R) were documented with 13% allelic frequency in lung adenocarcinoma (Fig. 3C), whereas no mutations were detected in both the components of biphasic mesothelioma, although it was unclear whether tumor cells harbored BAP1 mutations because Ion AmpliSeq Cancer Hot Panel v2 does not include BAP1. The patient is alive and well, with no evidence of disease recurrence 7 months after surgery. The gene discussed is EGFR; the disease is lung adenocarcinoma.